Gilead and Merck report 48-week HIV results
Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) said their once-weekly HIV pill maintained suppression through Week 48 in two Phase 3 trials.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) said their once-weekly HIV pill maintained suppression through Week 48 in two Phase 3 trials.
Bluejay Diagnostics (NASDAQ:BJDX) completed enrollment of 750 patients in its SYMON-II study evaluating 28-day sepsis mortality risk.
3M Company (NYSE:MMM) posted GAAP sales of $6.5 billion and adjusted sales of $6.5 billion for the second quarter of 2026.
KeyCorp (NYSE:KEY) reported Q2 net income of $472 million as taxable-equivalent revenue rose 6.7% to $1.96 billion.
General Motors (NYSE:GM) posted Q2 2026 revenue of $48 billion alongside a diluted earnings per share of $1.41.
Boeing (NYSE:BA) announced that Uganda Airlines has officially placed its first Boeing order for eight new aircraft.
Innate Pharma (NASDAQ:IPHA) completed patient enrollment in the dose escalation phase of its IPH4502 clinical study across 76 patients.
A long-inactive Ethereum (CRYPTO:ETH) wallet has become active again, transferring a significant amount of ETH to cryptocurrency trading firm Cumberland.
Leon Goldstein, a co-founder of Celsius Network, has agreed to pay more than US$6 million to settle allegations brought by the US Federal Trade Commission over his involvement with the collapsed cryptocurrency lender.
BitMine Immersion Technologies has expanded its Ethereum (CRYPTO:ETH) holdings to 5.78 million ETH following another purchase as part of its treasury strategy.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy